Immuno-oncology: Strategic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report includes coverage of immuno-oncology overview, trends, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment – major current and future players in the immuno-oncology field.

The global market value for bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, cytokines, and oncolytic viruses increased from $10.4 billion in 2014 to $74 billion in 2024.
This growth trajectory is expected to continue, with the total market reaching $186 billion by 2031, driven mainly by checkpoint modulators, followed closely by T-cell engagers.
China offers the broadest therapeutic access with 74 approved agents available, significantly more than the 53 agents accessible in the US, while non-small cell lung cancer is the indication with the highest number of approved immuno-oncology treatments.
Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.

Scope

This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and China) includes the following topics –

– Immuno-oncology (IO) overview

– Trends

– Classes of IO drugs – immune checkpoint modulators, bispecific T-cell engagers, cell therapy, cytokine therapeutics, cancer vaccines, and oncolytic viruses

– Leading marketed and pipeline products

– Market analysis

– Regulatory landscape and market access

– Opportunities, challenges, and unmet needs

– Commercial assessment – major current and future players in the IO field

Key Highlights

This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China).

The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.

Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market.

The base year of the sales forecast model is 2023, and the forecast period is 2023-2033.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global immuno-oncology therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global immune-oncology therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie
Allogene Therapeutics
Amgen
AstraZeneca
BioNTech
BMS
Candel Therapeutics
CG Oncology
CRISPR Therapeutics
Daiichi-Sankyo
Dendreon Pharmaceuticals
Genmab
Gilead Sciences
Greenwich LifeSciences
Iovance Therapeutics
Johnson & Johnson
Kite
Legend Biotech
Merck & Co.
Novartis
Oncolytics Biotech
Regeneron
Replimune
Roche
Sanofi
Xilio Therapeutics

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Immuno-oncology Overview

3.1. What is IO?

3.2. What is IO According to Regulators?

3.3. Most Important Milestones of IO Development Globally

3.4. Key Chat on X

4. Trends

4.1. Industry Trends – Bispecific Antibodies

4.2. Industry Trends – Cancer Vaccines

4.3. Industry Trends – Cell Therapies

4.4. Industry Trends – Checkpoint Modulators

4.5. Industry Trends – Cytokines

4.6. Industry Trends – Oncolytic Viruses

4.7. Regulatory Trends

5. IO Classification

5.1. Industry Trends – Bispecific Antibodies

5.2. Bispecific Antibodies

5.3. Cancer Vaccines

5.4. Cell Therapies

5.5. Checkpoint Modulators

5.6. Next-generation Cytokines

5.7. Oncolytic Viruses

5.8. IO in Clinical Trials

6 Marketed Products

6.1. IO Marketed Products in the 8MM

6.2. Total Market Size for IO Agents

6.3. 10 Highest-Grossing IO Treatments in 2024

6.4. Leading Checkpoint Modulators in the 8MM

6.5. Leading T Cell Engagers in the 8MM

6.6. Leading Cancer Vaccines and Oncolytic Viruses in the 8MM

6.7. Leading Cell Therapies in the 8MM

6.8. Emerging IO Therapies

7 Pipeline Products

7.1. IO Pipeline Products in the 8MM

7.2. Future Outlook of IO Agents, According to High-Prescribing Physicians

7.3. Consensus Forecast Sales for the Top Three Pipeline Candidates per IO Class

7.4. The Forecast Highest-Grossing Bispecific Antibody Products

7.5. The Forecast Highest-Grossing Vaccine Products

7.6. The Forecast Highest-Grossing Cell Therapy Products

7.7. The Forecast Highest-Grossing Checkpoint Modulator Products

7.8. The Forecast Highest-Grossing Cytokine Products

7.9. The Forecast Highest-Grossing Oncolytic Virus Products

8. Market Analysis

8.1. Market Analysis and Forecast of the Six Classes of IO Agents

8.2. Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space

8.3. Latest Strategic Partnership Deals in the IO Space

8.4. Top 10 Mergers and Acquisitions that Include IO Assets: 2020–2025

8.5. Latest Mergers and Acquisitions that Include IO Assets

9. Regulatory and Market Access

9.1. IO in Clinical Trials

9.2. Endpoints in IO Clinical Trials – KOL Perspective

9.3. Challenges in IO Clinical Trials – KOL Perspective

9.4. Regulatory and Market Access – US

9.5. Regulatory and Market Access – EU

9.6. Regulatory and Market Access – Japan

9.7. Regulatory and Market Access – China

9.8. Early Access Schemes

9.9. Barriers to Access According to High Prescribers

10. Opportunities, Challenges, and Unmet Needs

10.1. Bispecific Antibodies

10.2. Cancer Vaccines

10.3. Cell Therapies

10.4. Checkpoint Modulators

10.5. Cytokines

10.6. Oncolytic Viruses

10.7. Clinical Unmet Needs in IO – Gap Analysis

10.8. Commercial Unmet Needs in IO – Gap Analysis

10.9. Unmet Needs – KOL Perspective

10.10. Unmet Needs According to High Prescribers

10.11. R&D Strategies

10.12. Opportunities for the Industry – Modern Approaches & Collaboration

10.13. Closing Remarks – In Their Words

11. Companies

11.1. Drug Development Scorecard

11.2. Current Major Players – Novartis

11.3. Current Major Players – Merck & Co.

11.4. Current Major Players – Gilead Sciences

11.5. Current Major Players – Roche

11.6. Current Major Players – BMS

11.7. Current Major Players – AstraZeneca

11.8. Current Major Players – Sanofi

11.9. Current Major Players – Amgen

11.10. Current Major Players – Dendreon Pharmaceuticals

11.11. Current Major Players – Legend Biotech

11.12. Current Major Players – Johnson & Johnson

11.13. Current Major Players – Daiichi-Sankyo

11.14. Current Major Players – Kite

11.15. Current Major Players – Regeneron

11.16. Current Major Players – AbbVie

11.17. Future Players Based on Pipeline Strength – Genmab

11.18. Future Players Based on Pipeline Strength – Iovance Therapeutics

11.19. Future Players Based on Pipeline Strength – Replimune

11.20. Future Players Based on Pipeline Strength – CG Oncology

11.21. Future Players Based on Pipeline Strength – BioNTech

11.22. Future Players Based on Pipeline Strength – CRISPR Therapeutics

11.23. Future Players Based on Pipeline Strength – Allogene Therapeutics

11.24. Future Players Based on Pipeline Strength – Xilio Therapeutics

11.25. Future Players Based on Pipeline Strength – Candel Therapeutics

11.26. Future Players Based on Pipeline Strength – Oncolytics Biotech

11.27. Future Players Based on Pipeline Strength – Greenwich LifeSciences

12. Appendix

12.1. Sources

12.2. Primary Research

12.3. Key Themes Impacting the Pharmaceutical Industry

12.4. Our Thematic Research Methodology

12.5. About the Authors

13. Contact Us

Immuno-oncology: Strategic Intelligence standard reports
Currency USD
$14,999

Can be used by individual purchaser only

$44,997

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Immuno-oncology: Strategic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Immuno-oncology: Strategic Intelligence in real time.

  • Access a live Immuno-oncology: Strategic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.